Featured Listing

AlphaMaven

Company Logo'

Venture Capital Featured Listing

BrookDell Partners

Back

Private Equity

Andrea Alms Video:  Money In Motion 143 - 2024 Cancer Research Breakthroughs

February 2025 - Private Equity

posted by BrookDell Partners

TRANSCRIPT


Hello, my name is Andrea Alms I'm a technology investor and financial manager. And this is your money in motion. Over the past year, MD Anderson researchers have investigated the gut microbes. Examined the earliest origins of lung cancer and tested therapies. Their breakthroughs in cancer research continue to drive forward our mission to stop cancer. Here are some of the top three of the 11.


Novel MD Anderson research highlights. Number one eating beans improve gut health. Regulate immune and inflammatory processes in colorectal cancer survivors. The beacon trial examined the effects of adding one cup of cooked white navy bean. Per day to the diets of participants with a history of colorectal cancer. Participants saw an increase in beneficial bacteria. A decrease in harmful bacteria in their gut.


After eight weeks, both diet and gut health include. Microbiome balance. It plays a role in the prevention of implant inflammation. Cancer and cardiovascular disease that impact the health and longevity of colorectal cancer survivors. Number two Parp inhibitors plus immunotherapy. Lower risk of endometrial cancer versus chemotherapy alone. As you may recall in earlier episodes, I explained. One Parp inhibitors inhibit cancer cells from healing itself, and two remember cancer.


Chemotherapy kills both healthy and cancer cells. So by slowing and stopping the cancer cells from healing itself and also taking drugs to improve your immune system. This is help. Stage three for your endometrial cancer patients. Number three novel many inhibitors show promise for patients with advanced acute myeloma leukemias. The combination of Ribadu, a type of netting inhibitor, and a hypo methyl Hela agent and BCL two inhibitor, led to FDA approval of the drug for adults and pediatric patients with relapsed or refractory advanced acute leukemia.


Yes, sorry for all the technical jargon. However, the point is that cancer is now being personally and specifically targeted to help you. The individual before as one size fits all. So lots of jargon. That's a good thing. Please feel free to visit MD Anderson's website to check out the 11 new cancer Research breakthroughs. Thank you. This is your money.


Your money in motion.



ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.